BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 37777506)

  • 21. PD-L1 siRNA-mediated silencing in acute myeloid leukemia enhances anti-leukemic T cell reactivity.
    van Ens D; Mousset CM; Hutten TJA; van der Waart AB; Campillo-Davo D; van der Heijden S; Vodegel D; Fredrix H; Woestenenk R; Parga-Vidal L; Jansen JH; Schaap NPM; Lion E; Dolstra H; Hobo W
    Bone Marrow Transplant; 2020 Dec; 55(12):2308-2318. PubMed ID: 32528120
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PD-L1/PD-1 Pattern of Expression Within the Bone Marrow Immune Microenvironment in Smoldering Myeloma and Active Multiple Myeloma Patients.
    Costa F; Vescovini R; Marchica V; Storti P; Notarfranchi L; Dalla Palma B; Toscani D; Burroughs-Garcia J; Catarozzo MT; Sammarelli G; Giuliani N
    Front Immunol; 2020; 11():613007. PubMed ID: 33488620
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Study and analysis of antitumor resistance mechanism of PD1/PD-L1 immune checkpoint blocker.
    Wang Z; Wu X
    Cancer Med; 2020 Nov; 9(21):8086-8121. PubMed ID: 32875727
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Glycolytic activation of peritumoral monocytes fosters immune privilege via the PFKFB3-PD-L1 axis in human hepatocellular carcinoma.
    Chen DP; Ning WR; Jiang ZZ; Peng ZP; Zhu LY; Zhuang SM; Kuang DM; Zheng L; Wu Y
    J Hepatol; 2019 Aug; 71(2):333-343. PubMed ID: 31071366
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multi-Omics Perspective Reveals the Different Patterns of Tumor Immune Microenvironment Based on Programmed Death Ligand 1 (PD-L1) Expression and Predictor of Responses to Immune Checkpoint Blockade across Pan-Cancer.
    Huang K; Hu M; Chen J; Wei J; Qin J; Lin S; Du H
    Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34068143
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tumor-Associated Macrophages Regulate PD-1/PD-L1 Immunosuppression.
    Pu Y; Ji Q
    Front Immunol; 2022; 13():874589. PubMed ID: 35592338
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Enhanced Anti-Leukemic Effects through Induction of Immunomodulating Microenvironment by Blocking CXCR4 and PD-L1 in an AML Mouse Model.
    Hwang HS; Han AR; Lee JY; Park GS; Min WS; Kim HJ
    Immunol Invest; 2019 Jan; 48(1):96-105. PubMed ID: 30204524
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A phase 1b/2 study of azacitidine with PD-L1 antibody avelumab in relapsed/refractory acute myeloid leukemia.
    Saxena K; Herbrich SM; Pemmaraju N; Kadia TM; DiNardo CD; Borthakur G; Pierce SA; Jabbour E; Wang SA; Bueso-Ramos C; Loghavi S; Tang G; Cheung CM; Alexander L; Kornblau S; Andreeff M; Garcia-Manero G; Ravandi F; Konopleva MY; Daver N
    Cancer; 2021 Oct; 127(20):3761-3771. PubMed ID: 34171128
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia.
    Williams P; Basu S; Garcia-Manero G; Hourigan CS; Oetjen KA; Cortes JE; Ravandi F; Jabbour EJ; Al-Hamal Z; Konopleva M; Ning J; Xiao L; Hidalgo Lopez J; Kornblau SM; Andreeff M; Flores W; Bueso-Ramos C; Blando J; Galera P; Calvo KR; Al-Atrash G; Allison JP; Kantarjian HM; Sharma P; Daver NG
    Cancer; 2019 May; 125(9):1470-1481. PubMed ID: 30500073
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CD4
    Xiao M; Xie L; Cao G; Lei S; Wang P; Wei Z; Luo Y; Fang J; Yang X; Huang Q; Xu L; Guo J; Wen S; Wang Z; Wu Q; Tang J; Wang L; Chen X; Chen C; Zhang Y; Yao W; Ye J; He R; Huang J; Ye L
    J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35580929
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Programmed death-1 checkpoint blockade in acute myeloid leukemia.
    Sehgal A; Whiteside TL; Boyiadzis M
    Expert Opin Biol Ther; 2015; 15(8):1191-203. PubMed ID: 26036819
    [TBL] [Abstract][Full Text] [Related]  

  • 32. STAT5 is essential for inducing the suppressive subset and attenuate cytotoxicity of Vδ2
    Cheng C; Liang S; Yue K; Wu N; Li Z; Dong T; Dong X; Ling M; Jiang Q; Liu J; Huang XJ
    Cancer Lett; 2024 Apr; 587():216730. PubMed ID: 38360140
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PD-1 and PD-L1 inhibitors foster the progression of adult T-cell Leukemia/Lymphoma.
    Jalili-Nik M; Soltani A; Mashkani B; Rafatpanah H; Hashemy SI
    Int Immunopharmacol; 2021 Sep; 98():107870. PubMed ID: 34153661
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CD8
    Wang M; Bu J; Zhou M; Sido J; Lin Y; Liu G; Lin Q; Xu X; Leavenworth JW; Shen E
    Clin Immunol; 2018 May; 190():64-73. PubMed ID: 28893624
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model.
    Zhang L; Gajewski TF; Kline J
    Blood; 2009 Aug; 114(8):1545-52. PubMed ID: 19417208
    [TBL] [Abstract][Full Text] [Related]  

  • 36. What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 3: PD-L1, Intracellular Signaling Pathways and Tumor Microenvironment.
    Palicelli A; Croci S; Bisagni A; Zanetti E; De Biase D; Melli B; Sanguedolce F; Ragazzi M; Zanelli M; Chaux A; Cañete-Portillo S; Bonasoni MP; Soriano A; Ascani S; Zizzo M; Castro Ruiz C; De Leo A; Giordano G; Landriscina M; Carrieri G; Cormio L; Berney DM; Gandhi J; Copelli V; Bernardelli G; Santandrea G; Bonacini M
    Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830209
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MiR155 sensitized B-lymphoma cells to anti-PD-L1 antibody via PD-1/PD-L1-mediated lymphoma cell interaction with CD8+T cells.
    Zheng Z; Sun R; Zhao HJ; Fu D; Zhong HJ; Weng XQ; Qu B; Zhao Y; Wang L; Zhao WL
    Mol Cancer; 2019 Mar; 18(1):54. PubMed ID: 30925928
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High baseline tumor burden-associated macrophages promote an immunosuppressive microenvironment and reduce the efficacy of immune checkpoint inhibitors through the IGFBP2-STAT3-PD-L1 pathway.
    Wen Z; Sun H; Zhang Z; Zheng Y; Zheng S; Bin J; Liao Y; Shi M; Zhou R; Liao W
    Cancer Commun (Lond); 2023 May; 43(5):562-581. PubMed ID: 37031362
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Increased TOX expression concurrent with PD-1, Tim-3, and CD244 expression in T cells from patients with acute myeloid leukemia.
    Huang S; Liang C; Zhao Y; Deng T; Tan J; Zha X; Li Y; Chen S
    Cytometry B Clin Cytom; 2022 Mar; 102(2):143-152. PubMed ID: 34913594
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Preferential Expression of Programmed Death Ligand 1 Protein in Tumor-Associated Macrophages and Its Potential Role in Immunotherapy for Hepatocellular Carcinoma.
    Park DJ; Sung PS; Lee GW; Cho S; Kim SM; Kang BY; Hur W; Yang H; Lee SK; Lee SH; Jung ES; Seo CH; Ahn J; Choi HJ; You YK; Jang JW; Bae SH; Choi JY; Yoon SK
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33946835
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.